home / stock / gsgtf / gsgtf quote
Last: | $0.45 |
---|---|
Change Percent: | -6.67% |
Open: | $0.48 |
Close: | $0.45 |
High: | $0.48 |
Low: | $0.45 |
Volume: | 756 |
Last Trade Date Time: | 03/14/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.45 | $0.48 | $0.45 | $0.48 | $0.45 | 756 | 03-14-2024 |
$0.47 | $0.47 | $0.47 | $0.47 | $0.47 | 900 | 12-28-2023 |
$0.52 | $0.52 | $0.52 | $0.52 | $0.52 | 100 | 12-12-2023 |
$0.61 | $0.61 | $0.61 | $0.61 | $0.61 | 2,000 | 11-15-2023 |
$0.0003 | $0.0003 | $0.0003 | $0.0003 | $0.0003 | 100 | 10-04-2023 |
$0.7 | $0.7 | $0.7 | $0.7 | $0.7 | 100 | 10-02-2023 |
$0.755 | $0.755 | $0.755 | $0.755 | $0.755 | 350 | 07-10-2023 |
$0.8 | $0 | $0.8 | $0 | $0 | 100 | 06-23-2023 |
$0.8 | $0 | $0.8 | $0 | $0 | 20 | 06-21-2023 |
$0.8 | $0 | $0.8 | $0 | $0 | 50 | 06-20-2023 |
$0.8 | $0.8 | $0.8 | $0.8 | $0.8 | 1,000 | 05-01-2023 |
$3.1 | $3.1 | $3.1 | $3.1 | $3.1 | 100 | 01-05-2023 |
$3.15 | $3.15 | $3.15 | $3.15 | $3.15 | 790 | 12-08-2022 |
$3.15 | $3.15 | $3.15 | $3.15 | $3.15 | 600 | 10-19-2022 |
$3.5 | $3.5 | $3.5 | $3.5 | $3.5 | 1,000 | 10-04-2022 |
$3.5 | $0 | $3.5 | $0 | $0 | 5 | 08-25-2022 |
$3.5 | $3.5 | $3.5 | $3.5 | $3.5 | 1,000 | 08-22-2022 |
$4.75 | $4.75 | $4.75 | $4.75 | $4.75 | 10,000 | 02-02-2022 |
$4.5 | $4.5 | $4.5 | $4.5 | $4.5 | 10,000 | 01-26-2022 |
$4.6 | $4.6 | $4.6 | $4.6 | $4.6 | 245 | 01-24-2022 |
News, Short Squeeze, Breakout and More Instantly...
GenSight Biologics SA Company Name:
GSGTF Stock Symbol:
OTCMKTS Market:
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2...
Advanced discussions ongoing to secure financing until resumption of early access program (AAC/AAP) expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III trial supporting both US and EU regulatory submissions for registration of LUMEVOQ ...
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calen...